Clinical efficacy and safety of irinotecan and docetaxel combined with cisplatin in the treatment of recurrent and drug-resistant small cell lung cancer

Minerva Med. 2023 Apr;114(2):260-262. doi: 10.23736/S0026-4806.22.08130-7. Epub 2022 Apr 26.

Authors

Xiting Liu¹, Qin Ma¹, Lei Yang¹, Chengbiao Li², Feng Gu¹, Hua Li³, Jie Lin⁴

Affiliations

¹ Department of Oncology, Gansu Provincial Cancer Hospital, Lanzhou, China.
² Department of Oncology, Wuwei City People's Hospital, Wuwei, China.
³ Department of Oncology, Pingliang People's Hospital, Pingliang, China.
⁴ Department of Urinary Surgery, Qianjiang Central Hospital of Chongqing, Chongqing, China - 36654737@qq.com.

PMID: 35470652
DOI: 10.23736/S0026-4806.22.08130-7

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cisplatin / therapeutic use
Docetaxel
Humans
Irinotecan / therapeutic use
Lung Neoplasms* / drug therapy
Small Cell Lung Carcinoma* / drug therapy
Treatment Outcome

Substances

Irinotecan
Docetaxel
Cisplatin